RocketTickers

Immunomedics Announces Positive Results from Pivotal Phase 2 TRO

Long
NASDAQ:IMMU   None
IMMU: Immunomedics
2020-09-19 11:00:10
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.